- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03270384
Re-establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease (ROBUST-II)
November 21, 2022 updated by: Urotronic Inc.
The study described below is designed to assess the safety and device performance for the drug coated balloon (DCB) for the treatment of urethral stricture.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa
-
-
Maryland
-
Hanover, Maryland, United States, 21076
- Chesapeake Urology
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
Woodbury, Minnesota, United States, 55125
- Metro Urology
-
-
Virginia
-
Virginia Beach, Virginia, United States, 23462
- Urology of Virginia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Male subjects ≥ 18 years' old
- Visual confirmation of stricture via cystoscopy or urethrogram
- Single lesion anterior urethral stricture less than or equal to 3 cm
- Two (2) or more prior diagnosis and treatment of stricture treatments (including self-catheterization) including DVIU (direct visual internal urethrotomy), but no prior urethroplasty
- Significant symptoms of stricture such as frequency of urination, dysuria, urgency, hematuria, slow flow, feeling of incomplete emptying, recurrent UTI's (urinary tract infections).
- IPSS (International Prostate Symptom Score) score of 13 or higher
- Lumen diameter <12F by urethrogram
- Able to complete validated questionnaire independently
- Qmax <12 ml/sec
- Guidewire must be able to cross the lesion
Exclusion Criteria:
- Strictures greater than 3.0 cm long.
- Subjects that have more than 1 stricture.
- Sensitivity to paclitaxel or on medication that may have negative interaction with paclitaxel
- Subjects who have a suprapubic catheter
- Previous urethroplasty within the anterior urethra
- Stricture due to bacterial urethritis or untreated gonorrhea
- Stricture dilated or incised within the last 3 months
- History of over active bladder or stress incontinence
- Previous radical prostatectomy
- Previous pelvic radiation
- Diagnosed kidney, bladder, urethral or ureteral stones or active stone passage in the past 6 months.
- Presence of a penile implant, artificial urinary sphincter, or stent(s) in the urethra or prostate
- Known neurogenic bladder, sphincter abnormalities, or poor detrusor muscle function
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Up to 15 subjects will be enrolled and treated with the Urotronic drug coated balloon (DCB)
|
The Urotronic Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip.
The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety- Rate of Device Related Serious Complications
Time Frame: 90 days
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety- Change in IIEF (International Index of Erectile Function)
Time Frame: 90 days
|
90 days
|
Efficacy- Stricture Recurrence Rate
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sean Elliott, MD, University of Minnesota
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 25, 2017
Primary Completion (Actual)
November 1, 2019
Study Completion (Anticipated)
June 1, 2024
Study Registration Dates
First Submitted
August 30, 2017
First Submitted That Met QC Criteria
August 31, 2017
First Posted (Actual)
September 1, 2017
Study Record Updates
Last Update Posted (Actual)
November 23, 2022
Last Update Submitted That Met QC Criteria
November 21, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PR1032
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urethral Stricture
-
Urotronic Inc.WithdrawnLower Urinary Tract Symptoms | Urethral Stricture | Urethral Stricture, Anterior | Anterior Urethral Stricture
-
University of California, San FranciscoRecruitingUrethral Stricture, MaleUnited States
-
University Hospital, GhentWithdrawnUrethral Stricture DiseaseBelgium
-
University Hospital, GhentCompletedAnterior Urethral Stricture, MaleBelgium
-
Lepu Medical Technology (Beijing) Co., Ltd.Recruiting
-
University Hospital Virgen de las NievesInstituto de Investigación Biosanitaria de Granada (ibs.Granada)RecruitingFibrosis | Hormone Deficiency | Urethral Stricture, MaleSpain
-
Ain Shams UniversityCompletedUrethral Stricture, MaleEgypt
-
Regenosca SARecruiting
-
Ain Shams UniversityCompletedUrethral StrictureEgypt
Clinical Trials on Urotronic Drug Coated Balloon (DCB)
-
Urotronic Inc.CompletedStricture UrethraUnited States
-
Medtronic EndovascularCompletedPeripheral Arterial Disease (PAD)Germany
-
MedtronicRecruitingFistula | Arteriovenous Fistula | Arteriovenous Fistula Stenosis | Arteriovenous Fistula OcclusionUnited States
-
Chinese PLA General HospitalUnknown
-
Shanghai Zhongshan HospitalRecruitingTakayasu ArteritisChina
-
MedtronicActive, not recruitingAtherosclerosis of Femoral Artery | Obstructive Disease | Atherosclerosis of Popliteal ArteryFrance
-
Seoul National University HospitalUnknownKor PCI - CAD Patients Treated With PCI: Analysis of the Korean Nationwide Health Insurance DatabaseCoronary Artery Disease | Drug-coated Balloon | Drug-eluting Stents
-
Medtronic EndovascularCompletedPopliteal Artery Stenosis | Popliteal Artery Occlusion | Femoral Artery Occlusion | Femoral Artery StenosisUnited States
-
Julie DawsonActive, not recruitingIschaemic Heart DiseaseUnited Kingdom
-
C. R. BardCompletedArteriosclerosis | Atherosclerosis | Vascular DiseaseGermany, Belgium